A plant extract composition for protecting skin from photothermal damage and use thereof

Abstract

The application discloses a kind of plant extract compositions and its application of photothermal damage skin resistance, the composition is by following weight parts Each raw material is mixed to form: Forsythia suspensa flower extract 60-90 parts, Saururus chinensis extract 5-15 parts, Eucommia bark extract 3-10 parts;Wherein, Forsythia suspensa flower extract total lignans content ≥8wt%;Saururus chinensis extract total lignans content ≥15wt%, total triterpenes content ≥25wt%;Eucommia bark extract coralwood glycoside content ≥8wt%, gardenia jasminoides content ≥2wt%.Advantages are, the synergistic effect of three plant extracts in composition on different key pathways that cause skin photothermal damage, form a complete theoretical logic closed, can synergistically solve the skin redness problem caused by capillary relaxation due to photothermal damage, good safety, can be widely applied in cosmetics and external medicine.

Description

Technical Field

[0001] This invention belongs to the field of cosmetics and topical skin preparations, and relates to a plant extract composition for resisting photothermal damage to the skin and its application. Specifically, it relates to a plant composition that can synergistically resist the combined photothermal damage caused by ultraviolet and infrared rays in sunlight and its application in the preparation of cosmetics, skin care products or pharmaceuticals that soothe skin redness, burning, pain and repair the skin barrier. Background Technology

[0002] Sunlight damage to the skin is a complex process, primarily involving ultraviolet (UV) radiation damage and infrared (IR) thermal damage. UV radiation can directly induce DNA damage, produce excessive reactive oxygen species, and trigger inflammatory responses. Infrared (IR) radiation mainly causes a significant increase in skin temperature through radiative heat effects, inducing a thermal stress response, causing abnormal capillary dilation and accelerated blood flow, resulting in persistent redness, burning sensations, and even pain. This process typically involves neurogenic inflammation and the release of vasoactive substances.

[0003] Currently, most sunscreens on the market primarily offer protection against UVB / UVA (two different wavelengths of ultraviolet radiation), but their effectiveness against heat damage caused by infrared radiation is limited. Furthermore, existing sunscreens are often single-function, typically targeting only inflammation or vascular responses, failing to create a complete protective loop encompassing heat perception, nerve conduction, vasodilation, and inflammatory responses. Therefore, developing a composition capable of multi-target, synergistic action to comprehensively address photothermal damage has significant application value and market potential. Summary of the Invention

[0004] This invention provides a plant extract composition for resisting photothermal damage to the skin and its application, aiming to at least partially overcome the shortcomings of the prior art. The plant extract composition provided by this invention can effectively resist the combined photothermal damage to the skin caused by ultraviolet and infrared rays in sunlight.

[0005] The technical solution of the present invention to solve the above-mentioned technical problems is as follows: a plant extract composition for resisting photothermal damage to the skin, which is composed of the following raw materials in parts by weight: 60-90 parts of Magnolia officinalis flower extract, 5-15 parts of Saururus chinensis extract, and 3-10 parts of Eucommia ulmoides bark extract; wherein, the total lignan content in the Magnolia officinalis flower extract is ≥8wt%; the total lignan content in the Saururus chinensis extract is ≥15wt%, and the total triterpenoid content is ≥25wt%; the content of arugula glycoside in the Eucommia ulmoides bark extract is ≥8wt%, and the content of geniposide is ≥2wt%.

[0006] Based on the above technical solution, the present invention can also make the following better or best choices.

[0007] Preferably, it is a mixture of the following raw materials in parts by weight: 75-85 parts of Magnolia officinalis flower extract, 10-14 parts of Saururus chinensis extract, and 6-8 parts of Eucommia ulmoides bark extract.

[0008] Ideally, it is a mixture of the following ingredients in parts by weight: 81 parts Magnolia officinalis flower extract, 12 parts Saururus chinensis extract, and 7 parts Eucommia ulmoides bark extract.

[0009] This invention provides a cosmetic comprising the above-described plant extract composition. The cosmetic provided by this invention is interpreted broadly, including both cosmetics and skincare products in the conventional sense.

[0010] Specifically, the product type of the cosmetic is any one of essence water, facial mask, serum, sunscreen, moisturizing gel, lotion or cream; preferably, the content of the plant extract composition in the cosmetic is 0.05wt%-2wt%, and the optimal content is usually controlled at 0.1wt%-1wt%.

[0011] The present invention also provides a topical medicine comprising a composition of plant extracts.

[0012] Specifically, the product type of the topical medicine is any one of cream, ointment, gel or patch; preferably, the content of the plant extract composition in the topical medicine is 0.05wt%-2wt%, and the optimal content is usually controlled at 0.1wt%-1wt%.

[0013] This invention also provides the use of the above-mentioned plant extract composition for resisting photothermal damage to the skin in the preparation of cosmetics or topical medicines for repairing photothermal damage to the skin, soothing redness, reducing skin temperature, and relieving burning pain. In application, the content of the plant extract composition in the cosmetic or topical medicine is 0.05wt%-2wt%, with the optimal content typically controlled at 0.1wt%-1wt%.

[0014] Compared with the prior art, the beneficial effects of the present invention are:

[0015] I. Multi-target and Complete Mechanism: The plant extract composition provided by this invention is not a simple additive combination, but rather a synergistic effect of three plant extracts working on different key pathways causing photothermal damage to the skin, forming a complete theoretical logical closure to synergistically solve the problem of skin redness caused by capillary dilation due to photothermal damage. Specifically: This composition reduces heat sensitivity at its source by inhibiting the expression of HSP70 induced by heat activation; it inhibits capillary dilation by reducing the production of PGE2; it significantly reduces capillary permeability by effectively inhibiting the expression of VGEF, preventing plasma leakage and tissue edema; and it inhibits abnormal blood flow increase and the formation of inflammatory edema and erythema from a neuroregulatory perspective by efficiently inhibiting the release of the key vasodilatory neuropeptide CGRP. In other words, it achieves effective inhibition of multiple pathways from heat-sensing signal transduction, vasodilation, and inflammatory factor signal amplification.

[0016] II. Synergistic Enhancement of Efficacy: The combination of the three plant extracts has a far superior effect on soothing redness caused by photothermal damage compared to using any single ingredient, resulting in a synergistic effect.

[0017] 3. High safety: All ingredients are plant-based, ensuring high safety and low irritation, making them suitable for sensitive skin.

[0018] IV. Wide range of applications: This composition can be easily added to various dosage forms of cosmetics or topical medicines, such as sunscreens, repair serums, soothing gels, face creams, lotions, ointments, gels or patches, etc. Detailed Implementation

[0019] The technical solutions provided by the present invention will be clearly and completely described below with reference to specific embodiments. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0020] To avoid unnecessary details, unless otherwise specified, all raw materials used in the following examples are commercially available products, and all methods used are conventional methods in the art.

[0021] The three plant extracts used in the following examples are all commercially available products, and the content of active ingredients in each extract meets the following requirements: the total lignan content in the Magnolia officinalis flower extract is ≥8wt%; the total lignan content in the Saururus chinensis extract is ≥15wt%, and the total triterpenoid content is ≥25wt%; the coral glycoside content in the Eucommia ulmoides bark extract is ≥8wt%, and the geniposide content is ≥2wt%.

[0022] Specifically, the Magnolia officinalis flower extract was purchased from Shanghai Jiakai Biotechnology Co., Ltd., under the trade name Solarepare MB. The full composition of this product is: 1,3-propanediol 88%, Magnolia officinalis flower extract 12%, and the total lignan content is ≥1%, which translates to a total lignan content of ≥8.33% in the Magnolia officinalis flower extract (calculated by dividing 1% by 12%). The Saururus chinensis extract was also purchased from Shanghai Jiakai Biotechnology Co., Ltd., under the trade name ErythcalmSC. The full composition of this product is: caprylic / capric triglyceride 96.5%, Saururus chinensis extract 3.5%, and the total lignan content is ≥0.6% and the total triterpenoid content is ≥1%, which translates to a total lignan content of ≥17.14% in the Saururus chinensis extract (calculated by dividing 0.6% by 3.5%) and a total triterpenoid content of ≥28.57% (calculated by dividing 1% by 3.5%). The Eucommia bark extract was purchased from Shanghai Baihaobo Biotechnology Co., Ltd., under the trade name EUCOOLAN. The full composition of this product is: water 69%, butylene glycol 30%, and Eucommia bark extract 1%. The product contains geniposide ≥200ppm and coral glycoside ≥800ppm. This translates to a geniposide content of ≥2% (calculated by dividing 200ppm by 1%) and a coral glycoside content of ≥8% (calculated by dividing 800ppm by 1%) in the Eucommia bark extract.

[0023] The plant extract compositions for protecting skin from photothermal damage (hereinafter referred to as the compositions) used in the following embodiments are all composed of the following raw materials in parts by weight: 81 parts of Magnolia officinalis flower extract, 12 parts of Saururus chinensis extract, and 7 parts of Eucommia ulmoides bark extract.

[0024] Example 1

[0025] Experimental study on the inhibition of HSP70 by the composition.

[0026] This experiment consisted of 5 groups, with 3 replicates per group, and each batch of experiments was independently repeated 3 times. The grouping and specific treatments for each group are as follows:

[0027]

[0028] The specific steps of the experimental study are as follows:

[0029] S1. Resuscitate and culture HaCaT at 37 ℃;

[0030] S2. Using 2×10 5 Cells / well were seeded into 6-well plates, 2 mL / well, and incubated at 37 ℃ for 20–24 h;

[0031] S3. Pretreatment of the test substance: Prepare a 10 wt% stock solution of the composition in PBS (i.e., the mass fraction of the composition in the prepared solution is 10%), and dilute the composition into three gradients with complete culture medium: high dose group: 0.5 wt%, medium dose group: 0.2 wt%, low dose group: 0.05 wt%;

[0032] S4. Discard the old solution, add 2 mL of culture medium containing the composition (containing 0.1% DMSO) to each well, shake gently to mix, and incubate at 37 ℃ for 1 h. Place the 6-well plate in a 43 ℃ constant temperature water bath with the water level level with the culture medium, and perform heat shock treatment for 30 min (±1 min). Immediately after the treatment, wipe the outer wall with 70 vol% ethanol, transfer it back to the 37 ℃ incubator, and continue incubation for 6 h.

[0033] S5. After incubation, cells were collected and qPCR was performed to detect the HSP70 gene. Each sample was tested three times, and the average Ct was taken. The relative expression level was calculated using the 2^–ΔΔCt method.

[0034] The results are as follows:

[0035]

[0036] The results showed that all three concentrations of the composition could effectively inhibit the expression of heat shock protein HSP70.

[0037] Example 2

[0038] Experimental study on the inhibition of PGE2 by the composition.

[0039] This experiment consisted of 5 groups, with 3 replicates per group. Each batch of experiments was independently repeated 3 times. The grouping and specific treatments for each group are as follows:

[0040]

[0041] The specific steps of the experimental study are as follows:

[0042] S1. Digest HaCaT with 0.25% trypsin, count the samples, and then measure the total number of samples at 1×10⁻⁶. 5 Cells / well were seeded into 48-well plates, 400 µL / well, and incubated at 37 ℃ for 18 h;

[0043] S2. Pretreatment of the test substance: Prepare a 10 wt% PBS solution of the composition stock solution, and dilute the composition into three gradients using serum-free DMEM: high-dose group: 0.5 wt%, medium-dose group: 0.2 wt%, low-dose group: 0.05 wt%;

[0044] S3. UVB treatment: Remove the cap, rinse gently once with PBS, leave 200 µL of thin liquid to prevent drying, place under a UVB lamp, irradiate with a dose of 30 mJ / cm², immediately after irradiation, replace with 400 µL of serum-free culture medium containing the drug, and continue incubation at 37 ℃ for 18 h.

[0045] S4. Collect cell supernatant and use the EILSA kit to detect PGE2 expression levels.

[0046] The results are as follows:

[0047]

[0048] The results showed that all three concentrations of the composition could effectively inhibit the expression of PGE2.

[0049] Example 3

[0050] Experimental study on the inhibition of CGRP by the composition.

[0051] This experiment consisted of 5 groups, with 3 replicates per group. Each batch of experiments was independently repeated 3 times. The grouping and specific treatments for each group are as follows:

[0052]

[0053] The specific steps of the experimental study are as follows:

[0054] S1. Digest HaCaT with 0.25% trypsin, count the samples, and then measure the total number of samples at 1×10⁻⁶. 5 Cells / well were seeded into 48-well plates, 200 µL / well, and incubated at 37 ℃ for 18 h;

[0055] S2. Test substance pretreatment: Prepare a 10 wt% PBS solution of the composition stock solution, and dilute the composition into three gradients using serum-free DMEM: high-dose group: 0.5 wt%, medium-dose group: 0.2 wt%, low-dose group: 0.05 wt%;

[0056] S3. UVB treatment: Remove the cap, rinse gently once with PBS, place under a UVB lamp, irradiate with a dose of 30 mJ / cm², immediately replace with 200 µL of serum-free culture medium containing the drug after irradiation, and continue incubation at 37 ℃ for 18 h.

[0057] S4. Collect cell supernatant and cell lysate separately and use a dedicated EILSA kit to detect CGRP expression levels. Then, sum the CGRP expression levels in the cell supernatant and cell lysate.

[0058] The results are as follows:

[0059]

[0060] The results showed that all three concentrations of the composition could effectively inhibit the expression and release of CGRP.

[0061] Example 4

[0062] Experimental study on the inhibition of VGEF by the composition.

[0063] This experiment consisted of 5 groups, with 3 replicates per group. Each batch of experiments was independently repeated 3 times. The grouping and specific treatments for each group are as follows:

[0064]

[0065] The specific steps of the experimental study are as follows:

[0066] S1. Digest HaCaT with 0.25% trypsin, count the samples, and then measure the total number of samples at 1×10⁻⁶. 5 Cells / well were seeded into 48-well plates, 200 µL / well, and incubated at 37 ℃ for 18 h;

[0067] S2. Pretreatment of the test substance: Prepare a 10 wt% PBS solution of the composition stock solution, and dilute the composition into three gradients using serum-free DMEM: high-dose group: 0.5 wt%, medium-dose group: 0.2 wt%, low-dose group: 0.05 wt%;

[0068] S3. UVB treatment: Remove the cap, rinse gently once with PBS, place under a UVB lamp, irradiate with a dose of 30 mJ / cm², immediately replace with 200 µL of serum-free culture medium containing the drug after irradiation, and continue incubation at 37 ℃ for 18 h.

[0069] S4. Collect cell supernatant and cell lysate separately and use EILSA kit to detect VGEF expression level, and sum the VGEF expression levels in cell supernatant and cell lysate.

[0070] The results are as follows:

[0071]

[0072] The results showed that all three concentrations of the composition could effectively inhibit VEGF expression.

[0073] Example 5 and Comparative Examples A to D

[0074] The composition is used in the preparation of a soothing serum to combat photothermal damage.

[0075] Formula composition (by weight):

[0076]

[0077] The above formula can be prepared using the conventional serum product preparation process.

[0078] The efficacy of the serums prepared in Example 5 and Comparative Example AD was evaluated in humans. Thirty healthy volunteers were selected and divided into five groups. Artificial light was used to simulate sunlight exposure on their backs to induce redness and burning sensations. The difference in erythema index before and after exposure was recorded. Volunteers were required to apply the product once daily. After 7 and 14 days of product use, the erythema index was measured using a skin colorimeter, and the rate of change was calculated.

[0079]

[0080] Compared to Comparative Example A, Example 5 and Comparative Examples BD both demonstrated, to varying degrees, the ability to promote the recovery of skin redness caused by photothermal damage.

[0081] Compared to Comparative Example BD, Example 5 demonstrated a strong ability to promote the recovery of skin redness caused by photothermal damage, indicating that the composition at this ratio has a stronger ability to reduce sunburn erythema than the single active ingredient at the same concentration.

[0082] Example 6 and Comparative Example E

[0083] The composition is used in the preparation of sunscreens that protect against photothermal damage.

[0084] Formula composition (by weight):

[0085]

[0086] Preparation process: Prepared according to the conventional emulsification process for sunscreen products, with the addition temperature of the composition below 60°C.

[0087] Example 6 and Comparative Example E were tested for SPF values ​​in humans according to the requirements of the Cosmetic Safety Technical Specifications. Each group consisted of 3 people, and the results are as follows:

[0088]

[0089] The results showed that, compared with Comparative Example E, the addition of the composition in Example 6 increased the SPF value by 21.6% and the PFA value by 15.1%. This indicates that the composition can effectively resist skin erythema caused by photothermal damage in sunscreen cosmetics, demonstrating the improvement in SPF and PFA values.

[0090] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A plant extract composition for protecting skin from photothermal damage, characterized in that, This product is a mixture of the following ingredients in parts by weight: 60-90 parts of Magnolia officinalis flower extract, 5-15 parts of Saururus chinensis extract, and 3-10 parts of Eucommia ulmoides bark extract; wherein the Magnolia officinalis flower extract is marketed under the name "Uweishu," and its total composition is: 88wt% 1,3-propanediol, 12wt% Magnolia officinalis flower extract, and a total lignan content ≥1wt%, which translates to a total lignan content ≥8.33wt% in the Magnolia officinalis flower extract; the Saururus chinensis extract is marketed under the name "Xiuyanyin," and its total composition is: 96.5wt% caprylic / capric triglyceride, Saururus chinensis extract, and... The total lignan content of this product is ≥0.6wt%, and the total triterpenoid content is ≥1wt%. This translates to a total lignan content of ≥17.14wt% and a total triterpenoid content of ≥28.57wt% in the *Saururus chinensis* extract. The trade name of the *Eucommia ulmoides* bark extract is EUCOOLAN. The complete composition of this product is: 69wt% water, 30wt% butylene glycol, and 1wt% *Eucommia ulmoides* bark extract. This product contains ≥200ppm geniposide and ≥800ppm argentinin. This translates to a ≥2wt% geniposide and ≥8wt% argentinin in the *Eucommia ulmoides* bark extract.

2. The plant extract composition for protecting skin from photothermal damage according to claim 1, characterized in that, It is a mixture of the following ingredients in parts by weight: 75-85 parts of Magnolia officinalis flower extract, 10-14 parts of Saururus chinensis extract, and 6-8 parts of Eucommia ulmoides bark extract.

3. The plant extract composition for protecting skin from photothermal damage according to claim 2, characterized in that, It is a mixture of the following ingredients in parts by weight: 81 parts Magnolia officinalis flower extract, 12 parts Saururus chinensis extract, and 7 parts Eucommia ulmoides bark extract.

4. A cosmetic product, characterized in that, A composition comprising the plant extracts according to any one of claims 1 to 3.

5. A cosmetic product according to claim 4, characterized in that, The cosmetic product type is any one of essence water, facial mask, serum, sunscreen, moisturizing gel, lotion or cream, and the content of the plant extract composition in the cosmetic is 0.05wt%-2wt%.

6. A topical medicine, characterized in that, A composition comprising the plant extracts according to any one of claims 1 to 3.

7. A topical medicine according to claim 6, characterized in that, The product type of the topical medicine is any one of cream, ointment, gel or patch, and the content of the plant extract composition in the topical medicine is 0.05wt%-2wt%.

8. The use of a plant extract composition for resisting photothermal damage to the skin as described in any one of claims 1 to 3 in the preparation of cosmetics or topical medicines for repairing photothermal damage to the skin, soothing redness, reducing skin temperature, and relieving burning pain.

9. The application according to claim 8, characterized in that, The content of the plant extract composition in cosmetics or topical medicines is 0.05wt%-2wt%.

10. The application according to claim 9, characterized in that, The content of the plant extract composition in cosmetics or topical medicines is 0.1wt%-1wt%.

Images